Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.1.3.1 (alkaline phosphatase)
 47,916 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The cases of fetal intrauterine hypotrophy syndrome were subjected to rest, dietetic and pharmacological treatment which included intravenous infusions of low molecular Dekstrane, intramuscular injections of Synacthen-Depot, Sadamine and Partusisten. The clear improvement of selected parameters of placenta efficiency during the management was observed. It included: mean increase of blood serum oxytocinase activity about 2.1 U, mean increase of quantity of estrogens excreted in 24-hour urine about 4.1 mg/24 hours, mean decrease of term-stabile alkaline phosphatase activity in blood serum about 16 U. The comparison of the state of hypotrophic newborns found in the group with hypotrophy treated during the course of pregnancy with the group of untreated hypotrophy permits to conclude: statistically significant more rarefied occurrence of newborns of low values according to Apgar scale, hypoglycemia, acidosis, anemia as well as respiratory distress syndrome and five-fold diminished perinatal mortality. It was demonstrated a clear correlation between many parameters of structure and activity of oxygenizing enzymes of placentae existed between the group with treated and untreated hypotrophy.
Ginekol Pol 1993 Mar
PMID:[Microstructure of placenta and activity of some respiratory enzymes --in pregnancy with treated and untreated fetal intrauterine hypotrophy syndrome]. 835 45

The aim of this study was to evaluate the clinical usefulness of the calcitonin test in predicting the hyperparathyroid bone disease severity in uremia. 200 IU of synthetic salmon calcitonin was given intranasally to 77 hemodialysed patients with end-stage renal failure. Before the test, serum calcium, PTH and serum alkaline phosphatase had been sampled; serum calcium was determined also in 2 to 4 hours after. The subjects were divided into 3 groups according to their serum PTH levels. Group I consisted of 24 patients with at least 10-fold serum PTH elevation, group II of 34 patients with intermediate values, and group III of 19 patients with serum PTH within normal range. In the group I the mean serum calcium fall was 0.32 +/- 0.16 mmol/l (1.28 +/- 0.64 mg/dl) (p < 0.001) and 0.27 +/- 0.15 mmol/l (1.08 +/- 0.60 mg/dl) (p < 0.001), after 2 to 4 hours respectively. In the group II serum calcium decreased by 0.16 +/- 0.12 mmol/l (0.64 +/- 0.48 mg/dl) after 2 hours and by 0.14 +/- 0.09 mmol/l (0.56 +/- 0.36 mg/dl) after 4 hours; the differences were statistically insignificant. In the group III no reduction in serum calcium was observed. In the whole 77 patients population significant linear correlations between the hypocalcemic response and iPTH as well as serum alkaline phosphatase were found. Our results confirm that the calcitonin-induced hypocalcemia a test can be, in addition to serum alkaline phosphatase and PTH evaluation, a simple and useful index of advanced hyperparathyroid bone disease in hemodialysed patients with chronic renal failure.
Pol Arch Med Wewn 1993 Feb
PMID:[Test with calcitonin as an index of parathyroid function in chronic renal failure]. 850 92

Standard therapy with orally administered active metabolites of vitamin D3 often does not satisfactorily control the biochemical manifestations of secondary hyperparathyroidism in uremic patients. This may be due to inadequate serum concentrations of 1,25 (OH)2D3 achieved during the treatment. Eighteen patients on chronic hemodialysis (HD) with severe hyperparathyroidism were given high doses of calcitriol (1,25 (OH)2D3) or alphacalcidol (1 alpha-OH-D3) orally, in ten evenings preceding each HD session. The effect of the treatment on circulating parathyroid hormone (PTH), serum hydroxyproline, serum alkaline phosphatase and bone isoenzyme was examined in a pilot study during 5 weeks. Irrespective the preparation given the treatment caused 71.7 +/- 22.2% reduction of intact serum PTH concentration with only moderate rise of serum calcium. A decrease of serum hydroxyproline and activity of alkaline phosphatase with its bone fraction, the direct indexes of bone turnover reduction, was also observed. With ongoing calcium carbonate therapy (3-6 g/day) 5 episodes of mild, asymptomatic hypercalcemia was observed for the 108 times of the total number of examinations; in those cases the dose of alphacalcidol was reduced. Our observations indicate that intermittent administration of 1,25 (OH)2D3 as well as 1 alpha-OH-D3 in high oral doses effectively suppress PTH synthesis in uremic hyperparathyroidism already in a couple of weeks. The effect is similar to that obtained with intravenous administration of the vitamin D3 active metabolites.
Pol Arch Med Wewn 1993 Feb
PMID:[Oral pulsatile therapy with active vitamin D3 metabolites--an efficient method of parathyroid hormone synthesis suppression in uremic patients with severe hyperparathyroidism. A pilot study]. 850 2

The aim of the investigation was to determine the effect of cryodestruction of the healthy prostate on general condition of dogs. The research was performed on 18 dogs divided into two groups: control and experimental. In the dogs from the experimental group after the laparotomy procedure the prostate was frozen in the repeated cycle using the flat cryoapplicator. The observations were carried out for 6 months. General condition of dogs was controlled, blood was examined and urine analysed. The performed determinations included the activity of alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, acid phosphatase and prostatic isoenzyme of acid phosphatase. It has been observed that the cryodestruction procedures of the prostatic gland are well tolerated by dogs. During 3 weeks after the surgery the number of leucocytes in blood increased. An increased drop of the blood cells was observed for 2 weeks after the procedure. Characteristic behaviour was observed in case of the prostatic isoenzyme of acid phosphatase. Immediately after the procedure the increased activity of that enzyme was observed and 24h later its decrease which remained for about 2 weeks. Then the isoenzyme activity increased again and that increase lasted for the period of 2 months.
Arch Vet Pol 1994
PMID:Organism reaction to cryodestruction of the prostatic gland in dogs. 859 Sep 8

The study was performed in 17 children with chronic renal failure, 7 were on hemodialysis, 6 on continuous ambulatory peritoneal dialysis, 4 were treated conservatively. In all, serum levels of alkaline phosphatase, PTH intact and osteocalcin were measured and bone biopsy was performed. We analyzed correlations between biochemical markers of bone metabolism and histomorphometric parameters. The lowest mean serum osteocalcin levels were found in children with adynamic bone disease, the highest with osteitis fibrosa. The serum osteocalcin level was significantly correlated with the dynamic parameter of bone formation rate (BFR), which suggests that this biochemical marker can be of use in discriminating between renal osteopathy with low and high bone turnover. Lack of correlation between serum osteocalcin level and mineralizing surface confirms it significance as a good marker of osteoblastic activity in bone formation but not in bone mineralization.
Pediatr Pol 1995 Dec
PMID:[Correlation between osteocalcin and bone histomorphometry in children with chronic renal failure]. 864 39

The occurrence and distribution pattern of spontaneous single-strand breaks (nicks) and/or gaps of mouse chromosomal DNA were studied with the help of nick-translation procedure omitting exogenous nucleases. The holoenzyme and a Klenow's fragment were used at a concentration of 0.I. U/20 microl of reaction mixture, resp. Bio-dUTP and streptavidin-alkaline phosphatase were used for labeling and detection. Chromosomes of postimplantation embryos and bone marrow were not stained. Chromosomes of all preimplantation stages of development were homogeneously stained with prominent dots of various size and intensities of grayish. DNA Pol I and the Klenow enzyme demonstrated a similar pattern of labelling. The centromeric heterochromatin was not labeled. The label was localized asymmetrically exclusive of NOR and telomeric regions.
 ...
PMID:[Single-stranded DNA breaks in the chromosomes of early mouse embryos]. 865 75

The effect of anti-cancer drugs on the metabolic efficiency of the liver was evaluated by means of phenazone (antipyrine) kinetics individually in each rat. Chlormethine (nitrogranulogen, NG), methotrexate (MTX), floxuridine (fluorouracil, 5-fluorouracil, 5-FU), cyclophosphamide (CY, endoxan), and three cytostatics applied jointly (MTX + 5-FU + CY) were administered ip to the rats, while antipyrine was given intravenously. The anti-cancer drugs: NG, MTX, 5-FU, CY and MTX + 5-FU + CY delayed the elimination of antipyrine. Statistically significant prolongation of the half-life, decrease in the elimination rate constant and the clearance of antipyrine have been found in the rats receiving anti-cancer drugs, as compared to the controls. After the administration of MTX, 5-FU, CY and the joint administration of MTX + 5-FU + CY the volume of distribution did not change, while the volume of distribution of antipyrine decreased after the administration of NG. The activity of the investigated enzymes, i.e., alanine aminotransferase (ALAT), aspartic aminotransferase (AspAT), gamma-glutamyltransferase (GGT), alkaline phosphatase (AP), which are the indicators of various liver dysfunctions, did not change after the administration of NG, MTX, 5-FU, CY and MTX + 5-FU + CY. The administered antineoplastic drugs in mono and polytherapy changed the activity of oxidase mixed function responsible for the metabolism of antipyrine. CY administered to rats in polytherapy had less influence on liver metabolic efficiency than in monotherapy.
Pol J Pharmacol
PMID:Effect of some anti-cancer drugs and combined chemotherapy on the pharmacokinetics of antipyrine in the rat. 886 74

Twenty-day administration of ochratoxin A (OA) at a dose of 1 mg/kg b.w. to one-day-old male chickens caused degenerative lesions in the epithelial cells of renal tubules and an advanced atrophy of bursal follicles which led to a marked reduction in the size of both bursal plicae and the whole organ. Moreover, a decrease in alkaline phosphatase activity in the brush border and an increase in acid phosphatase activity in the cytoplasm of the epithelial cells of renal tubules were found histochemically. An increase in acid phosphatase reaction in the cytoplasm of liver cells and in the hepatic intracellular spaces along with glycogen degeneration of hepatocytes was observed. However, a long-term (20 weeks) administration of 0.2 mg of OA/kg in feed caused no histopathological lesions indicating mycotoxin intoxication. In addition, no detectable (> 0.0005 mg/kg) ochratoxin residues were found in the kidneys, liver, and thigh and pectoral muscles.
Arch Vet Pol 1994
PMID:Experimental ochratoxicosis A in chickens. Histopathological and histochemical study. 889 Nov 75

The purpose of the study was to evaluate the effectiveness of the long-term oral pulse therapy with high doses of alphacalcidol (1 alpha (OH)D3) in severe uremic hyperparathyroidism. 43 hemodialysis patients with at least 5-fold 1-84 PTH serum elevation were given thrice a week oral (1 alpha (OH) D3) in doses up to 5 micrograms, according to serum calcium levels (monitored weekly). The drug was given in the evenings (Group A; 18 pts) or during hemodialysis sessions (Group B; 25 pts). The dialysate calcium was reduce to 1.40-1.45 mmol/l and CaCO3 was used as a main phosphate binder in doses up to 6 g/day; 13 pts received additionally small doses of Al (OH)3 (up to 3 g/day). After one month the PTH levels decreased by 67 +/- 7.7% (p < 0.001), while serum total calcium increased by 0.27 < or = 0.05 mmol/l. The parathyroid activity suppression progressed to 81 +/- 6.9% serum PTH reduction after 4 months and 74 +/- 6.1% fall after 8 months. Only 3 pts occurred to be non-responders; in 19 pts PTH levels normalized. A decrease of serum hydroxyproline and alkaline phosphatase with its bone isoenzyme activity was also observed with a direct correlation between those changes and parathyroid suppression. (1 alpha (OH) D3) dose at first month of therapy was 3.4 +/- 0.15 micrograms, but it was successively reduced because of hypercalcemia to a final dose of 2.2 +/- 0.22 micrograms. The frequency of hyperkalcemia was 7.6%; no difference between Group A and group B was noted. We conclude that oral (1 alpha (OH)D3) pulse therapy is very effective in the long-term parathyroid activity suppression in hemodialysis patients with severe hyperparathyroidism. To avoid dangerous hypercalcemia and relative hypoparathyroidism serum PTH and calcium levels should be carefully monitored.
Pol Arch Med Wewn 1996 Jul
PMID:[Long-term treatment with large doses of alphacalicidol in secondary hyperparathyroidism of patients dialyzed for end stage renal failure]. 896 41

Active vitamin D3 pulse therapy effectively suppresses parathormone (PTH) synthesis in uremic hyperparathyroidism but high serum levels of calcitriol achieved can induce direct osteoclastic resorption and block bone formation. Therefore we found it interesting to examine whether an addition of the osteoclast inhibitor, calcitonin (CT), could reduce those unwanted effects. 75 hemodialysis patients with at least 5-fold 1-84 PTH serum level elevation were divided into 4 treatment groups: I (n = 19)-CT and 1 alpha-OH-D3; II (n = 20)-CT; III (n = 19)-1 alpha-OH-D3 (n = 10) or 1.25 (OH)2D3 (n = 9) alone; IV (n = 17)-none of these drugs. CT (200 IU) and 1 alpha-OH-D3/1.25(OH)2D3 (up to 5 micrograms) were given 3 times a week. Dialysate Ca was 1.40-1.45 (Group I, III) or 1.95-2.00 mmol/l (Group II, IV). Within 8 months serum 1-84 PTH fell by 75% (p < 0.001) in Group I and by 77% (p < 0.001) in Group II, serum Ca increased by 0.22 +/- 0.05 mmol/l in Group I (p < 0.005) and by 0.25 +/- 0.05 mmol/l in Group III (p < 0.005), alkaline phosphatase activity decreased by 35% in Group I (p < 0.01) and 31% in Group III (p < 0.005) whereas in Groups II and IV no significant changes were noted. In Group III no differences between patients taking 1 alpha-OH-D3 or 1.25 (OH)2D3 were observed. The significant reduction of serum hydroxyproline (37%; p < 0.001) was seen only in Group 1. The increase in bone mineral density (BMD) measured by dual-energy X-ray absorptiometry was greater in Group I than in Group III (p < 0.05). In Group II the effect was mostly insignificant, whereas in Group IV a substantial decrease (p < 0.001) in BMD was observed. These data suggest that combined therapy with CT and oral 1 alpha-OH-D3 pulses is more effective than pulses alone in inhibiting bone resorption and in increasing BMD in hemodialysis patients with uremic hyperparathyroid bone disease.
Pol Arch Med Wewn 1996 Jul
PMID:[Combined therapy with calcitonin and high doses of active vitamin D3 metabolites in uremic hyperparathyroidism]. 896 42


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>